FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005312938> ?p ?o ?g. }

• W2005312938 endingPage "425" @default.
• W2005312938 startingPage "413" @default.
• W2005312938 abstract "British Journal of Clinical PharmacologyVolume 4, Issue 4 p. 413-425 Free Access The assessment of beta-adrenoceptor blocking drugs in man. DG McDevitt, DG McDevittSearch for more papers by this author DG McDevitt, DG McDevittSearch for more papers by this author First published: August 1977 https://doi.org/10.1111/j.1365-2125.1977.tb00756.xCitations: 117AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References ABELMANN, W.H. & FAREEDUDDIN, K. (1969). Increased tolerance of orthostatic stress in patients with heart disease. Am. J. Cardiol., 23, 354– 363. ABLAD, B., ERVIK, M., HALLGREN, J., JOHNSSON, G. & SOLVELL, L. (1972). Pharmacological effects and serum levels of orally administered alprenolol in man. Eur. J. clin. Pharmac., 5, 44– 52. AHLQUIST, R.P. (1948). A study of the adrenotropic receptors. Am. J. Physiol., 153, 586– 599. BLINKS, J.R. (1967). Evaluation of the cardiac effects of several β-adrenergic blocking agents. Ann. N.Y. Acad. Sci., 139, 673– 685. BODEM, G. & CHIDSEY, C.A. (1973). Pharmacokinetic studies of practolol, a β-adrenergic antagonist in man. Clin. Pharmac. Ther., 14, 26– 29. BOURNE, H.R., THOMSON, P.D. & MELMON, K.L. (1970). Diagnosis and treatment of β-adrenergic receptor hyper-responsiveness: A critical appraisal. Arch. int. Med., 125, 1063– 1066. BRIANT, R.H., DOLLERY, C.T., FENYVESI, T. & GEORGE, C.F. (1973). Assessment of selective β-adrenoceptor blockade in man. Br. J. Pharmac., 49, 106– 114. BRICK, I., HUTCHISON, K.J., McDEVITT, D.G., RODDIE, I.C. & SHANKS, R.G. (1968). Comparison of the effects of I.C.I. 50, 172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br. J. Pharmac., 36, 35– 45. BROWN, H.C., CARRUTHERS, S.G., KELLY, J.G., McDEVITT, D.G. & SHANKS, R.G. (1976). Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur. J. clin. Pharmac., 9, 367– 372. BROWN, H.C., CARRUTHERS, S.G., JOHNSTON, G.D., KELLY, J.G., McAINSH, J., McDEVITT, D.G. & SHANKS, R.G. (1976). Clinical pharmacologic observations on atenolol, a β-adrenoceptor blocker. Clin. Pharmac. Ther., 20, 524– 534. CARRUTHERS, S. G., GHOSAL, A., McDEVITT, D.G., NELSON, J.K. & SHANKS, R.G. (1974). The assessment of β-adrenoceptor blocking drugs in hyperthyroidism. Br. J. clin. Pharmac., 1, 93– 98. CARRUTHERS, S.G., KELLY, J.G., McDEVITT, D.G. & SHANKS, R.G. (1974). Blood levels of practolol after oral and parenteral administration and their relationship to exercise. Clin. Pharmac. Ther., 15, 497– 509. CARRUTHERS, S.G., SHANKS, R.G. & McDEVITT, D.G. (1976). Intrinsic heart rate on exercise and β-adrenoceptor blockade. Br. J. clin. Pharmac., 3, 991– 999. CHAMBERLAIN, D.A., TURNER, P. & SNEDDON, J.M. (1967). Effects of atropine on heart-rate in healthy man. Lancet, ii, 12– 15. CLEAVELAND, C.R., RANGNO, R.E. & SHAND, D.G. (1972). A standardized isoproterenolol sensitivity test. Arch. int. Med., 130, 47– 52. CLEAVELAND, C.R. & SHAND, D.G. (1972). Effect of route of administration on the relationship between β-adrenergic blockade and plasma propranolol level. Clin. Pharmac. Ther., 13, 181– 185. COLTART, DJ., GIBSON, D.G. & SHAND, D.G. (1971). Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br. med. J., 1, 490– 491. COLTART, DJ. & MELDRUM, S.J. (1970). The effect of propranolol on the human and canine transmembrane action potential. Br. J. Pharmac., 40, 148P. COLTART, DJ. & SHAND, D.G. (1970). Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br. med. J., 3, 731– 734. CONOLLY, M.E., DAVIES, D.S., DOLLERY, C.T. & GEORGE, C.F. (1971). Resistance to β-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Br. J. Pharmac., 43, 389– 402. COOKSON, D.N. & REED, C.F. (1963). A comparison of the effects of isoproterenol in the normal and asthmatic subject: A preliminary report. Am. Rev. resp. Dis., 88, 636– 643. CUTHBERT, M.F. & COLLINS, R.F. (1975). Plasma levels and β-adrenoceptor blockade with acebutolol, practolol and propranolol in man. Br. J. clin. Pharmac., 2, 49– 55. DONALD, D.E. (1974). Myocardial performance after excision of the intrinsic cardiac nerves in the dog. Circulation Res., 34, 417– 424. DUNLOP, D. SHANKS, R.G. (1968). Selective blockade of adrenoceptive β-receptors in the heart. Br. J. Pharmac., 32, 201– 218. ECKBERG, D.L., DRABINSKY, M.I. & BRAUNWALD, E. (1971). Defective cardiac parasympathetic control in patients with heart disease. New Engl. J. Med., 285, 877– 883. EVANS, G.H., NIES, A.S. & SHAND, D.G. (1973). The disposition of propranolol III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J. Pharmac. exp. Ther., 186, 114– 122. FITZGERALD, J.D. (1970). A new test for the degree of adrenergic β-receptor blockade. Int. J. clin. Pharmac., 4, 125– 130. FITZGERALD, J.D. & O'DONNELL, S.R. (1971). Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br. J. Pharmac., 43, 222– 235. FITZGERALD, J.D. & SCALES, B. (1968). Effect of a new adrenergic beta-blocking agent (I.C.I. 50, 172) on heart rate in relation to its blood levels. Int. J. clin. Pharmac., 16, 467– 474. FROLICH, E.D., TARAZI, R.C. & DUSTAN, H.P. (1969). Hyperdynamic beta-adrenergic circulatory state: Increased beta-receptor responsiveness. Arch. int. Med., 123, 1– 7. GEORGE, C.F. (1975). Problems in assessing β-adrenoceptor antagonism in man. Br. J. clin. Pharmac., 2, 3– 4. GEORGE, C.F., CONOLLY, M.E., FENYVESI, T., BRIANT, R. & DOLLERY, C.T. (1972). Intravenously administered isoproteronal sulphate dose-response curves in man. Arch. int. Med., 130, 361– 364. GEORGE, C.F., FENYVESI, T., CONOLLY, M.E. & DOLLERY, C.T. (1972). Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. Eur. J. clin. Pharmac., 4, 74– 76. GEORGE, C.F., FENYVESI, T. & DOLLERY, C.T. (1973). Pharmacological effects of propranolol in relation to plasma levels. In Biological effects of drugs in relation to their plasma concentrations, ed. D.S. Danes & B.N.C. Pickard, pp. 123– 133. London: Macmillan. GOLDSTEIN, A., ARONOW, L. & KALMAN, S.M. (1974). In Principles of drug action: The basis of pharmacology. New York: John Wiley & Sons, Inc. HARRY, J.D., KNAPP, M.F., LINDEN, RJ., NEWCOMBE, C.P. & STOKER, J.B. (1975). A test which may demonstrate in man intrinsic sympathomimetic activity of β-adrenoceptor blocking drugs. Br. J. clin. Pharmac., 2, 374P. JACKSON, G., ATKINSON, L. & ORAM, S. (1975). Reassessment of failed beta-blocker treatment in angina pectoris by peak exercise heart rate measurements. Br. med. J., 3, 616– 618. JOHNSSON, G., SVEDMYR, N. & THIRINGER, G. (1975). Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics. Eur. J. clin. Pharmac., 8, 175– 180. JOSE, A.D. (1966). Effect of combined sympathetic and parasympathetic blockade on heart rate and cardiac function in man. Am. J. Cardiol., 18, 476– 478. KOFI-EKUE, J.M., SHANKS, R.G. & WALSH, M.J. (1974). Observations on the effect of β-adrenoceptor blocking drugs on glyceryl trinitrate tachycardia. Br. J. clin. Pharmac., 1, 19– 26. KUMANA, C.R., KAYE, CM., LEIGHTON, M., TURNER, P. & HAMER, J. (1975). Cardiac and pulmonary effects of acebutolol. Lancet, ii, 89– 93. KUMANA, C.R., MARLIN, G.E., KAYE, C.M. & SMITH, D.M. (1974). New approach to assessment of cardioselectivity of beta-blocking drugs. Br. med. J., 4, 444– 447. LANDS, A.M., LUDUENA, F.P. & BUZZO, H.J. (1967). Differentiation of receptors responsive to isoproterenol. Life Sci., 6, 2241– 2249. LERTORA, J.J.L., MARK, A.L., JOHANNSEN, UJ., WILSON, W.R. & ABBOUD, F.M. (1975). Selective β-rpreceptor blockade with oral practolol in man. A dose-related phenomenon. J. clin. Invest., 56, 719– 724. LIND, A.R., TAYLOR, S.H., HUMPHREYS, P.W., KENNELLY, B.M. & DONALD, K.W. (1964). The circulatory effects of sustained voluntary muscle contraction. Clin. Sci., 27, 229– 244. LONDON, G.M., SAPAR, M.E., WEISS, Y.A. & MILLIEZ, P.L. (1976). Isoproterenol sensitivity and total body clearance of propranolol in hypertensive patients. J. clin. Pharmac., 16, 174– 182. McDEVITT, D.G., BROWN, H.C., CARRUTHERS, S.G. & SHANKS, R.G. (1977). Observations on the influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade in man. Clin. Pharmac. Ther., 21, 556– 566. McDEVITT, D.G., FRISK-HOLMBERG, M., HOLLIFIELD, J.W. & SHAND, D.G. (1976). Plasma binding and the affinity of propranolol for a β-receptor in man. Clin. Pharmac. Ther., 20, 152– 157. McDEVITT, D.G. & SHAND, D.G. (1975). Plasma concentrations and the time course of β-blockade due to propranolol. Clin. Pharmac. Ther., 18, 708– 713. MACDONALD, H.R., SAPRU, R.P., TAYLOR, S.H. & DONALD, K.W. (1966). Effects of intravenous propranolol on the systemic circulatory response to sustained hand grip. Am. J. Cardiol., 18, 333– 343. MORALES-AGUILERA, A. & VAUGHAN, WILLIAMS E.M. (1965). The effects on cardiac muscle of β-receptor antagonists in relation to their activity as local anaesthetics. Br. J. Pharmac., 24, 332– 338. NELSON, J.K. & McDEVITT, D.G. (1975). Comparative trial of propranolol and practolol in hyperthyroidism. Br. J. clin. Pharmac., 2, 411– 418. NIGAM, P.D. & MALHOTRA, A.S. (1973). Prolonged action of pindolol. Br. med. J., 1, 742– 743. PATERSON, J.W., CONOLLY, M.E., DOLLERY, C.T., HAYES, A. & COOPER, R.G. (1970). The pharmacodynamics and metabolism of propranolol in man. Eur. J. clin. Pharmac., 2, 127– 133. PERRIER, D. & GIBALDI, M. (1974). Drug concentrations in the plasma as an index of pharmacological effect. J. clin. Pharmac., 14, 415– 417. POWELL, C.E. & SLATER, I.H. (1958). Blocking of inhibitory adrenergic receptors by a dichloro-analogue of isoproterenol. J. Pharmac. exp. Ther., 122, 480– 488. POWLES, R., SHINEBOURNE, E. & HAMER, J. (1969). Selective cardiac sympathetic blockade as an adjunct to bronchodilator therapy. Thorax, 24, 616– 618. RIEGELMAN, S., LOO, J.C. & ROWLAND, M. (1968). Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit the properties of a single compartment. J. pharm. Sci., 57, 117– 123. ROBINSON, B.F., EPSTEIN, S.E., BEISER, C.D. & BRAUNWALD, E. (1966). Control of the heart rate by the autonomic nervous system: studies in man between baro-receptor mechanisms and exercise. Circulation Res., 19, 400– 411. ROBINSON, S., PEARCY, M., BRUECKMAN, F.R., NICHOLAS, J.R. & MILLER, D.L. (1953). Effects of atropine on heart rate and oxygen intake in working man. J. Appl. Physiol., 5, 508– 512. SHANKS, R.G. (1966). The pharmacology of β-sympathetic blockade. Am. J. Cardiol., 18, 308– 316. THIRINGER, G. & SVEDMYR, N. (1976). Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics. Eur. J. clin. Pharmac., 10, 163– 170. TURNER, P. (1974). β-adrenergic receptor blocking drugs in hyperthyroidism. Drugs, 7, 48– 54. VILJOEN, J.F., ESTAFANOUS, F.G. & KELLNER, G.A. (1972). Propranolol and cardiac surgery. J. thor. cardiovasc. Res., 64, 826. VILSVIK, J.S. & SCHAANNING, J. (1976). Effect of atenolol on ventilatory and cardiac function in asthma. Br. med. J., 2, 453– 455. WIENER, L., DWYER, E.M. & COX, J.W. (1969). Haemodynamic effects of nitroglycerin, propranolol and their combination in coronary artery disease. Circulation, 24, 623– 632. ZACEST, R. & KOCHWESER, J. (1972). Relation of propranolol plasma level to β-blockade during oral therapy. Pharmacology, 7, 178– 184. ZWEIFLER, A.J. & HANSSON, L. (1976). Heart rate responses during treatment of hypertension with propranolol. The clinical usefulness of the nitroglycerin test. Clin. Pharmac. Ther., 19, 403– 409. Citing Literature Volume4, Issue4August 1977Pages 413-425 ReferencesRelatedInformation" @default.
• W2005312938 created "2016-06-24" @default.
• W2005312938 creator A5033956548 @default.
• W2005312938 date "1977-08-01" @default.
• W2005312938 modified "2023-09-24" @default.
• W2005312938 title "The assessment of beta-adrenoceptor blocking drugs in man." @default.
• W2005312938 cites W119243411 @default.
• W2005312938 cites W1571135826 @default.
• W2005312938 cites W1596686713 @default.
• W2005312938 cites W163837500 @default.
• W2005312938 cites W1856121689 @default.
• W2005312938 cites W1943659055 @default.
• W2005312938 cites W1974338697 @default.
• W2005312938 cites W1976824259 @default.
• W2005312938 cites W1977110464 @default.
• W2005312938 cites W1985319965 @default.
• W2005312938 cites W1988121988 @default.
• W2005312938 cites W1989988736 @default.
• W2005312938 cites W1991425792 @default.
• W2005312938 cites W1995803479 @default.
• W2005312938 cites W1996607088 @default.
• W2005312938 cites W1998550557 @default.
• W2005312938 cites W2003661335 @default.
• W2005312938 cites W2003720738 @default.
• W2005312938 cites W2005785161 @default.
• W2005312938 cites W2009955124 @default.
• W2005312938 cites W2014074558 @default.
• W2005312938 cites W2014823356 @default.
• W2005312938 cites W2015394973 @default.
• W2005312938 cites W2018711737 @default.
• W2005312938 cites W2022221767 @default.
• W2005312938 cites W2023355925 @default.
• W2005312938 cites W2031432073 @default.
• W2005312938 cites W2036077696 @default.
• W2005312938 cites W2055013000 @default.
• W2005312938 cites W2056619965 @default.
• W2005312938 cites W2064654027 @default.
• W2005312938 cites W2081481884 @default.
• W2005312938 cites W2083850374 @default.
• W2005312938 cites W2085729239 @default.
• W2005312938 cites W2085934312 @default.
• W2005312938 cites W2087876837 @default.
• W2005312938 cites W2089274173 @default.
• W2005312938 cites W2090191850 @default.
• W2005312938 cites W2090538187 @default.
• W2005312938 cites W2092637448 @default.
• W2005312938 cites W2093374965 @default.
• W2005312938 cites W2111578975 @default.
• W2005312938 cites W2114857415 @default.
• W2005312938 cites W2116626785 @default.
• W2005312938 cites W2118424883 @default.
• W2005312938 cites W2134587236 @default.
• W2005312938 cites W2139490592 @default.
• W2005312938 cites W2159410311 @default.
• W2005312938 cites W2166579376 @default.
• W2005312938 cites W2170588986 @default.
• W2005312938 cites W2281938476 @default.
• W2005312938 cites W2396536432 @default.
• W2005312938 cites W2404633480 @default.
• W2005312938 cites W2407464743 @default.
• W2005312938 cites W2411669409 @default.
• W2005312938 cites W2413743035 @default.
• W2005312938 cites W2417064268 @default.
• W2005312938 cites W2418367722 @default.
• W2005312938 cites W2420372778 @default.
• W2005312938 cites W2462862544 @default.
• W2005312938 cites W2471249636 @default.
• W2005312938 cites W2992123833 @default.
• W2005312938 cites W4289951113 @default.
• W2005312938 cites W4300834643 @default.
• W2005312938 cites W80340148 @default.
• W2005312938 cites W2067931867 @default.
• W2005312938 cites W2170036245 @default.
• W2005312938 cites W2288266794 @default.
• W2005312938 doi "https://doi.org/10.1111/j.1365-2125.1977.tb00756.x" @default.
• W2005312938 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1429044" @default.
• W2005312938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20123" @default.
• W2005312938 hasPublicationYear "1977" @default.
• W2005312938 type Work @default.
• W2005312938 sameAs 2005312938 @default.
• W2005312938 citedByCount "129" @default.
• W2005312938 countsByYear W20053129382014 @default.
• W2005312938 countsByYear W20053129382016 @default.
• W2005312938 countsByYear W20053129382017 @default.
• W2005312938 crossrefType "journal-article" @default.
• W2005312938 hasAuthorship W2005312938A5033956548 @default.
• W2005312938 hasBestOaLocation W20053129382 @default.
• W2005312938 hasConcept C126322002 @default.
• W2005312938 hasConcept C144745244 @default.
• W2005312938 hasConcept C170493617 @default.
• W2005312938 hasConcept C185592680 @default.
• W2005312938 hasConcept C199360897 @default.
• W2005312938 hasConcept C2776174256 @default.
• W2005312938 hasConcept C2778151854 @default.
• W2005312938 hasConcept C2908894505 @default.
• W2005312938 hasConcept C2909341992 @default.
• W2005312938 hasConcept C31258907 @default.
• W2005312938 hasConcept C40465926 @default.

• next